MedCity News February 25, 2025
Medicare Part D spending on 10 diabetes drugs increased 364% between 2019 and 2023.
Medicare Part D spending on 10 diabetes drugs reached $35.8 billion in 2023, a 364% increase from 2019 at $7.7 billion, according to a February report from the Office of Inspector General (OIG).
At the same time, Medicare Part D enrollment has increased 12% to 50.5 million enrollees in 2023 from 44.9 million in 2019, the report showed.
For the report, the OIG selected 10 common type 2 diabetes drugs and analyzed trends in spending for these drugs, as well as trends in the number of enrollees prescribed these drugs. The drugs selected for the report include Mounjaro, Rybelsus, Ozempic, Trulicity, Bydureon, Victoza, Byetta, Invokana, Jardiance...
Today's Sponsors
Today's Sponsor